文献速递精神分裂症与精神病性障碍

抗精神病药在急性期精神分裂症成人中的长期疗效:系统综述与网络荟萃分析

Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis.
PubMed 文献 · World Psychiatry · 2023-01-01

该系统综述与网络荟萃分析纳入45项至少6个月的随机盲法试验、共11238例急性期精神分裂症成人患者,比较第二代抗精神病药与18种第一代抗精神病药的长期疗效。结果显示,奥氮平在总体症状改善上平均优于齐拉西酮、阿塞那平、伊潘立酮、帕利哌酮、氟哌啶醇、喹硫平、阿立哌唑和利培酮,但奥氮平对阿立哌唑和利培酮的95%CI包含微小效应可能;奥氮平对体重增加的影响高于所有其他抗精神病药。

要点

  • 奥氮平长期总体症状疗效优于多种抗精神病药,但对阿立哌唑和利培酮的差异可能微小。
  • 奥氮平对体重增加的影响高于所有其他抗精神病药,需权衡疗效与副作用。
  • 奥氮平与鲁拉西酮、氨磺必利、奋乃静、氯氮平、佐替平的差异小或不确定。

核心结论

  • 奥氮平在长期治疗中比多种其他抗精神病药更有效,但其疗效必须与副作用特征权衡。

研究设计与样本

  • 系统综述与网络荟萃分析,检索Cochrane精神分裂症组注册库至2022年3月6日,纳入45项至少6个月的随机盲法试验,共11238例参与者。

主要发现

  • 在总体症状上,奥氮平平均优于齐拉西酮(SMD=0.37,95%CI:0.26-0.49)、阿塞那平(SMD=0.33,95%CI:0.21-0.45)、伊潘立酮(SMD=0.32,95%CI:0.15-0.49)、帕利哌酮(SMD=0.28,95%CI:0.11-0.44)、氟哌啶醇(SMD=0.27,95%CI:0.14-0.39)、喹硫平(SMD=0.25,95%CI:0.12-0.38)、阿立哌唑(SMD=0.16,95%CI:0.04-0.28)和利培酮(SMD=0.12,95%CI:0.03-0.21)。
  • 奥氮平对阿立哌唑和利培酮的95%CI包含微小效应可能。
  • 奥氮平与鲁拉西酮、氨磺必利、奋乃静、氯氮平、佐替平的差异小或不确定。
  • 在体重增加方面,奥氮平的影响高于所有其他抗精神病药,平均差异从与齐拉西酮比较的-4.58 kg(95%CI:-5.33至-3.83)到与氨磺必利比较的-2.30 kg(95%CI:-3.35至-1.25)。

临床怎么用

  • 对于急性期精神分裂症成人患者的长期治疗,可考虑奥氮平因其总体症状疗效优于多种药物,但需密切监测体重增加等代谢副作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most acute phase antipsychotic drug trials in schizophrenia last only a few weeks, but patients must usually take these drugs much longer. We examined the long-term efficacy of antipsychotic drugs in acutely ill patients using network meta-analysis. We searched the Cochrane Schizophrenia Group register up to March 6, 2022 for randomized, blinded trials of at least 6-month duration on all second-generation and 18 first-generation antipsychotics. The primary outcome was change in overall symptoms of schizophrenia; secondary outcomes were all-cause discontinuation; change in positive, negative and depressive symptoms; quality of life, social functioning, weight gain, antiparkinson medication use, akathisia, serum prolactin level, QTc prolongation, and sedation. Confidence in the results was assessed by the CINeMA (Confidence in Network Meta-Analysis) framework. We included 45 studies with 11,238 participants. In terms of overall symptoms, olanzapine was on average more efficacious than ziprasidone (standardized mean difference, SMD=0.37, 95% CI: 0.26-0.49), asenapine (SMD=0.33, 95% CI: 0.21-0.45), iloperidone (SMD=0.32, 95% CI: 0.15-0.49), paliperidone (SMD=0.28, 95% CI: 0.11-0.44), haloperidol (SMD=0.27, 95% CI: 0.14-0.39), quetiapine (SMD=0.25, 95% CI: 0.12-0.38), aripiprazole (SMD=0.16, 95% CI: 0.04-0.28) and risperidone (SMD=0.12, 95% CI: 0.03-0.21). The 95% CIs for olanzapine versus aripiprazole and risperidone included the possibility of trivial effects. The differences between olanzapine and lurasidone, amisulpride, perphenazine, clozapine and zotepine were either small or uncertain. These results were robust in sensitivity analyses and in line with other efficacy outcomes and all-cause discontinuation. Concerning weight gain, the impact of olanzapine was higher than all other antipsychotics, with a mean difference ranging from -4.58 kg (95% CI: -5.33 to -3.83) compared to ziprasidone to -2.30 kg (95% CI: -3.35 to -1.25) compared to amisulpride. Our data suggest that olanzapine is more efficacious than a number of other antipsychotic drugs in the longer term, but its efficacy must be weighed against its side effect profile.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Leucht S, Schneider-Thoma J, Burschinski A, et al. Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis. World Psychiatry. 2023. PMID: 37159349. doi:10.1002/wps.21089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。